Eurofins Genomics Buys VBC-Biotech Businesses, Establishes Austrian Subsidiary
By LabMedica International staff writers Posted on 18 Nov 2014 |
Eurofins Genomics (Ebersberg, Germany) has acquired VBC-Biotech's (Vienna, Austria) oligonucleotide synthesis and DNA sequencing businesses, and an Austrian subsidiary is being established.
Eurofins MWG Operon is an international provider of genomic services established around the core business lines next generation sequencing (NGS), custom DNA sequencing, oligonucleotides, siRNA, and gene synthesis. A team of experts and a broad range of technologies in the field of genomic services, forensics, agroscience, pharmaceutical, environmental, food and feed testing, underline the approach to offer best praxis solutions and versatile concepts.
Eurofins Genomics is the genomics division of the Eurofins Scientific Group. The Austrian subsidiary called Eurofins Genomics AT and headquartered in Vienna, will leverage Eurofins' global network, production capacity, and infrastructure. "The new direct presence in Austria will provide value to our customers by demonstration our commitment to this market," Eurofins Genomics AT Managing Director Siegfried Schnabl said in a statement. "Furthermore, Vienna will serve as a perfect hub for future business into Central and Eastern Europe and beyond."
The joint company is located in Vienna. All VBC-Biotech's services have been integrated into the Eurofins Genomics business units.
Financial and other terms of the deal were not disclosed.
Related Links:
Eurofins Genomics
VBC-Biotech's
Eurofins MWG Operon is an international provider of genomic services established around the core business lines next generation sequencing (NGS), custom DNA sequencing, oligonucleotides, siRNA, and gene synthesis. A team of experts and a broad range of technologies in the field of genomic services, forensics, agroscience, pharmaceutical, environmental, food and feed testing, underline the approach to offer best praxis solutions and versatile concepts.
Eurofins Genomics is the genomics division of the Eurofins Scientific Group. The Austrian subsidiary called Eurofins Genomics AT and headquartered in Vienna, will leverage Eurofins' global network, production capacity, and infrastructure. "The new direct presence in Austria will provide value to our customers by demonstration our commitment to this market," Eurofins Genomics AT Managing Director Siegfried Schnabl said in a statement. "Furthermore, Vienna will serve as a perfect hub for future business into Central and Eastern Europe and beyond."
The joint company is located in Vienna. All VBC-Biotech's services have been integrated into the Eurofins Genomics business units.
Financial and other terms of the deal were not disclosed.
Related Links:
Eurofins Genomics
VBC-Biotech's
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance